MYOMO, INC. (MYO) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Myomo, Inc. is a wearable medical robotics company developing myoelectric orthotics (MyoPro) for patients with neuromuscular disorders. The company operates as a single segment, selling directly to patients (direct billing) and to Orthotics and Prosthetics (O&P) providers. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $9.65 million | $7.52 million | $19.48 million | $11.28 million |
| Gross Profit | $6.05 million | $5.33 million | $12.66 million | $7.62 million |
| Gross Margin | 62.7% | 70.8% | 65.0% | 67.6% |
| Net Loss | $(4.63) million | $(1.12) million | $(8.10) million | $(4.96) million |
| Operating Cash Flow | N/A | N/A | $(11.54) million | $(5.16) million |
| Cash & Equivalents (End of Period) | $14.24 million (June 30, 2025) | |||
| Total Debt (Current + Long-term) | $4.00 million (June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 28% quarter-over-quarter and 73% year-over-year (YTD), driven by higher unit volume and increased average selling prices following CMS fee updates effective January 2025.
- Margin Compression: Gross margin declined from 70.8% to 62.7% in Q2 2025. This was primarily due to higher material costs and increased manufacturing overhead (payroll and lease costs) associated with the new Burlington, MA headquarters and manufacturing facility.
- Expense Expansion: Operating expenses rose significantly. Selling, clinical, and marketing expenses increased 88% QoQ due to higher advertising spend and clinical headcount. R&D expenses nearly doubled (99% QoQ) to accelerate product development.
- Debt Utilization: The company drew $2.5 million on its revolving line of credit and $1.5 million on a new term loan facility during Q2 2025, totaling $4.0 million in debt outstanding.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash, cash equivalents, and short-term investments (~$15.5 million) are sufficient to fund operations for at least the next 12 months. However, the company continues to incur net losses and negative operating cash flow.
- Reimbursement Risks: A significant risk is the reliance on third-party payers. Medicare Advantage plans have reduced authorizations since late 2024. Additionally, CMS billing contractors initiated pre-payment audits in two regions, resulting in some claim denials currently under appeal.
- Operational Disruptions: A temporary payment hold by a Medicare Administrative Contractor (DME MAC) regarding the company's address change increased accounts receivable by approximately $1.5 million in Q2, though these claims have since been paid.
- Internal Controls: The company disclosed a material weakness in internal control over financial reporting related to IT general controls (privileged access rights and user provisioning). Remediation efforts are underway, but the weakness remains as of June 30, 2025.
- Market Factors: Changes in social media advertising algorithms in Q1 2025 negatively impacted lead generation and increased cost per pipeline addition, a trend expected to impact H2 2025 revenue growth.
Investor Verification Checklist
- Verify the status of the material weakness in internal controls and the timeline for full remediation.
- Monitor the outcome of CMS pre-payment audits and the trend in Medicare Advantage authorizations.
- Assess the sustainability of gross margin given the new facility overhead and potential tariff impacts on imported materials.
- Review the effectiveness of advertising spend in generating qualified leads following recent algorithm changes.
- Track the company's ability to achieve cash flow breakeven given the current burn rate and debt obligations.